DBV Technologies | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
Acadia Pharmaceuticals USD 237.8M 72.86M 2024-12
Alnylam Pharmaceuticals USD 523.15M 32.8M 2025-03
Amarin USD 16.28M 26.49M 2024-09
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
DBV Technologies -30442000 30.56M 2024-09
Halozyme Therapeutics USD 255.95M 15.3M 2024-12
Incyte USD 985.09M 111.22M 2025-03
Insmed USD 78.29M 6.04M 2024-12
Ionis Pharmaceuticals USD 130.15M 92.6M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
PTC Therapeutics USD 196.89M 10.95M 2024-12
Sarepta Therapeutics USD 526.11M 150.63M 2024-12
Ultragenyx Pharmaceutical USD 147.98M 29.51M 2024-12
United Therapeutics USD 701.9M 41.9M 2025-03



DBV Technologies Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.